| Literature DB >> 18195338 |
Amir Qaseem1, Vincenza Snow, Paul Shekelle, Donald E Casey, J Thomas Cross, Douglas K Owens, Paul Dallas, Nancy C Dolan, Mary Ann Forciea, Lakshmi Halasyamani, Robert H Hopkins, Paul Shekelle.
Abstract
RECOMMENDATION 1: In patients with serious illness at the end of life, clinicians should regularly assess patients for pain, dyspnea, and depression. (Grade: strong recommendation, moderate quality of evidence.) RECOMMENDATION 2: In patients with serious illness at the end of life, clinicians should use therapies of proven effectiveness to manage pain. For patients with cancer, this includes nonsteroidal anti-inflammatory drugs, opioids, and bisphosphonates. (Grade: strong recommendation, moderate quality of evidence.) RECOMMENDATION 3: In patients with serious illness at the end of life, clinicians should use therapies of proven effectiveness to manage dyspnea, which include opioids in patients with unrelieved dyspnea and oxygen for short-term relief of hypoxemia. (Grade: strong recommendation, moderate quality of evidence.) RECOMMENDATION 4: In patients with serious illness at the end of life, clinicians should use therapies of proven effectiveness to manage depression. For patients with cancer, this includes tricyclic antidepressants, selective serotonin reuptake inhibitors, or psychosocial intervention. (Grade: strong recommendation, moderate quality of evidence.) RECOMMENDATION 5: Clinicians should ensure that advance care planning, including completion of advance directives, occurs for all patients with serious illness. (Grade: strong recommendation, low quality of evidence.).Entities:
Mesh:
Year: 2008 PMID: 18195338 DOI: 10.7326/0003-4819-148-2-200801150-00009
Source DB: PubMed Journal: Ann Intern Med ISSN: 0003-4819 Impact factor: 25.391